Hidalgo-Tenorio C, Sadyrbaeva-Dolgova S, Enriquez-Gomez A, Munoz P, Plata-Ciezar A, Miro JM, Alarcon A, Martinez-Marcos FJ, Loeches B, Escrihuela-Vidal F, Vinuesa D, Herrero C, Boix-Palop L, Del Mar Arenas M, Vazquez EG, de Las Revillas FA, Pasquau J; EN-DALBACEN study group. EN-DALBACEN 2.0 Cohort: real-life study of dalbavancin as sequential/consolidation therapy in patients with infective endocarditis due to Gram-positive cocci. Int J Antimicrob Agents. 2023 Sep;62(3):106918. doi: 10.1016/j.ijantimicag.2023.106918. Epub 2023 Jul 11. PubMed PMID: 37442488.
AÑO: 2023; IF: 10.8